Boan Grants Shaphar Right to Commercialize BA5101 in China

Boan Biotech today announced a strategic partnership with Shanghai Pharmaceutical Co., Ltd. (Shaphar), granting the latter the exclusive right to market and distribute its Dulaglutide Injection (code-...

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Next Day Disclosure Return

Articles of Association

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2025, APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR, CHANGES IN THE COMPOSITION OF BOARD COMMITTEES AND AMENDMENTS OF THE ARTICLES OF ASSOCIATION

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025

PLACING OF NEW SHARES UNDER GENERAL MANDATE

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025

Boan Biotech Presents Early Research Findings about Its Innovative Anti-CD25 Antibody (BA1106) at AACR Annual Meeting 2025

Yantai, April 29, 2025 – Boan Biotech presented the early research findings about its BA1106, a non-IL-2 blocking anti-CD25 antibody, at the 2025 Annual Meeting of the American Association for C...